Eli Lilly (LLY) Payables (2009 - 2026)

Eli Lilly (LLY) has reported Payables for 18 consecutive years, with $5.0 billion the latest figure, recorded in Q1 2026.

• Payables for Q1 2026 came in at $5.0 billion, up 46.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 46.11% YoY), and the FY2025 annual result was $5.4 billion, up 17.57% from the prior year.
• Payables was $5.0 billion for Q1 2026 at Eli Lilly, down from $5.4 billion in the prior quarter.
• Over five years, Payables peaked at $5.4 billion in Q2 2025 and troughed at $1.4 billion in Q1 2022.
• Average Payables over 5 years is $3.4 billion, with a median of $3.4 billion recorded in 2025.
• Year-over-year, Payables decreased 12.58% in 2022 and surged 47.66% in 2025.
• Over 5 years, Payables stood at $2.9 billion in 2022, then increased by 27.82% to $3.8 billion in 2023, then grew by 21.43% to $4.6 billion in 2024, then gained by 17.57% to $5.4 billion in 2025, then retreated by 6.51% to $5.0 billion in 2026.
• Per Business Quant data, the three most recent Payables figures were $5.0 billion in Q1 2026, $5.4 billion in Q4 2025, and $4.3 billion in Q3 2025.